Boehringer Ingelheim Paves the Way for Important Market Launches
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
This development is driven by strong demand for key products in Human Pharma, in particular Jardiance at € 4.3 billion and OFEV at € 2.0 billion, which continue to make a significant difference for patients worldwide.
Building on this momentum, Boehringer Ingelheim is advancing its late-stage pipeline, with several therapies close to regulatory approval. These include zongertinib for HER2-mutated lung cancer and nerandomilast for pulmonary fibrosis, both of which recently delivered positive approval results and are working towards a potential launch in the second half of 2025.
“At Boehringer Ingelheim, our commitment to transforming lives for generations is more than a mission — it's a responsibility we carry forward every day. Therapies like Jardiance and OFEV continue to make a real difference to patients — they exemplify what’s possible when true innovation addresses unmet medical needs,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma. “At the same time, we’re making strong progress across our pipeline — from obesity to liver and kidney health — with the goal of redefining standards of care. As we prepare for the potential launches of zongertinib and nerandomilast later this year, we remain focused on delivering meaningful solutions. We understand the urgency behind every patient’s need, and we’re acting with speed and purpose to meet it.”
CFO Frank Hübler added: “In a volatile environment, we are delivering according to plan, with robust sales performance across our portfolio in human and animal health. As we prepare for major launches, we are investing more than ever – focusing on speed, scale, and impact to ensure we are ready to deliver innovative therapies to change the course of serious diseases. Beyond the excitement of new launches, we also see substantial growth potential in our established products, particularly with Jardiance, which continues to make a meaningful difference for patients worldwide.”
As we enter the second half of 2025, Boehringer Ingelheim is well-positioned to build on the performance of the first half and expects a positive year-on-year increase in net sales. With major product launches, a robust pipeline, and strategic investments in R&D and manufacturing, Boehringer Ingelheim is poised to expand its global footprint and bring innovative healthcare solutions to more patients and animals worldwide.
